Trial reportHuman psychopharmacology2014
Rimonabant effects on anxiety induced by simulated public speaking in healthy humans: a preliminary report.
Trial report in Human psychopharmacology, 2014. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 9 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
9 citing papers in PubMed, 31 citations in OpenAlex.
- Dose-related effects of delta-9-THC on emotional responses to acute psychosocial stress.Drug and alcohol dependence · 2017Trial
- Endocannabinoids and related lipids in blood plasma following touch massage: a randomised, crossover study.BMC research notes · 2015Trial
- Medical Cannabis in Children.Rambam Maimonides medical journal · 2020Review
- Endocannabinoid System Components as Potential Biomarkers in Psychiatry.Frontiers in psychiatry · 2020Review
- Endocannabinoid System Alterations in Posttraumatic Stress Disorder: A Review of Developmental and Accumulative Effects of Trauma.Chronic stress (Thousand Oaks, Calif.) · 2019Article
- Neurobiological Interactions Between Stress and the Endocannabinoid System.Neuropsychopharmacology : official publication of the American College of Neuropsychopharmacology · 2016Review
- Endocannabinoid signaling mediates oxytocin-driven social reward.Proceedings of the National Academy of Sciences of the United States of America · 2015Article
- Endocannabinoids and striatal function: implications for addiction-related behaviours.Behavioural pharmacology · 2015Review
- Stress regulates endocannabinoid-CB1 receptor signaling.Seminars in immunology · 2014Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
13 authors at 6 institutions in 2 countries.
Funding
Abstract
objectiveWe investigated the hypothesis that rimonabant, a cannabinoid antagonist/inverse agonist, would increase anxiety in healthy subjects during a simulation of the public speaking test.
methodsParticipants were randomly allocated to receive oral placebo or 90 mg rimonabant in a double-blind design. Subjective effects were measured by Visual Analogue Mood Scale. Physiological parameters, namely arterial blood pressure and heart rate, also were monitored.
resultsTwelve participants received oral placebo and 12 received 90 mg rimonabant. Rimonabant increased self-reported anxiety levels during the anticipatory speech and performance phase compared with placebo. Interestingly, rimonabant did not modulate anxiety prestress and was not associated with sedation, cognitive impairment, discomfort, or blood pressure changes.
conclusionsCannabinoid-1 antagonism magnifies the responses to an anxiogenic stimulus without interfering with the prestress phase. These data suggest that the endocannabinoid system may work on-demand to counteract the consequences of anxiogenic stimuli in healthy humans.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.